TARS Since 2020 Annualized Return and Average Annual Return

TARS Average Annual Return Chart Since 2020
Growth of $10,000.00
Without Dividends Reinvested Into TARS

Also see:
• TARS stock yearly return 2021
• TARS stock yearly return 2022
• TARS stock yearly return 2023
• TARS stock yearly return 2024
• TARS stock yearly return 2025
• TARS YTD return
Average Annual Return Benchmarks
Compare TARS average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
TARS Share Performance
TARS Average Annual Return Table Since 2020
Start date: 10/19/2020
End date: 05/14/2026
Start price/share: $22.00
End price/share: $65.18
Dividends collected/share: $0.00
Total return: 196.27%
TARS Average Annual Return: 21.53%
Starting investment: $10,000.00
Ending investment: $29,626.17
Years: 5.57


TARS average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. Co. is focused on the development and commercialization of therapeutics, starting with eye care. Co.'s lead product candidate, XDEMVY is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. The TARS average annual return since 2020 is shown above.

The Average Annual Return on the TARS average annual return since 2020 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether TARS average annual return since 2020 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the TARS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
TARS Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree TARS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
Tarsus Pharmaceuticals (TARS) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

TBIO Average Annual Return
TCMD Average Annual Return
TCRT Average Annual Return
TCRX Average Annual Return
TDOC Average Annual Return
TECH Average Annual Return
TECX Average Annual Return
TELA Average Annual Return
TELO Average Annual Return
TENX Average Annual Return
More Healthcare companies »
 

TARS Average Annual Return Since 2020 | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.